Vascular Solutions Company Profile (NASDAQ:VASC)

About Vascular Solutions (NASDAQ:VASC)

Vascular Solutions logoVascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company's product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company's product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Diagnostic & Testing Equipment
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:VASC
  • CUSIP: 92231M10
  • Web:
Average Prices:
  • 50 Day Moving Avg: $55.89
  • 200 Day Moving Avg: $51.22
  • 52 Week Range: $25.06 - $57.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 38.10
  • P/E Growth: 0.00
  • Net Margins: 13.02%
  • Return on Equity: 15.78%
  • Return on Assets: 14.30%
  • Current Ratio: 6.37%
  • Quick Ratio: 4.66%
  • Average Volume: 272,766 shs.
  • Beta: 0.98

Frequently Asked Questions for Vascular Solutions (NASDAQ:VASC)

What is Vascular Solutions' stock symbol?

Vascular Solutions trades on the NASDAQ under the ticker symbol "VASC."

How were Vascular Solutions' earnings last quarter?

Vascular Solutions, Inc. (NASDAQ:VASC) announced its quarterly earnings data on Monday, July, 25th. The company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.30 by $0.03. The business earned $41.20 million during the quarter, compared to analyst estimates of $41.40 million. Vascular Solutions had a return on equity of 15.78% and a net margin of 13.02%. The company's revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 earnings per share. View Vascular Solutions' Earnings History.

Where is Vascular Solutions' stock going? Where will Vascular Solutions' stock price be in 2017?

4 analysts have issued 1 year price targets for Vascular Solutions' stock. Their forecasts range from $53.00 to $58.00. On average, they anticipate Vascular Solutions' stock price to reach $55.50 in the next twelve months. View Analyst Ratings for Vascular Solutions.

Who are some of Vascular Solutions' key competitors?

How do I buy Vascular Solutions stock?

Shares of Vascular Solutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Solutions' stock price today?

One share of Vascular Solutions stock can currently be purchased for approximately $56.00.

MarketBeat Community Rating for Vascular Solutions (NASDAQ VASC)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Vascular Solutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vascular Solutions (NASDAQ:VASC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $55.50 (0.89% downside)
Consensus Price Target History for Vascular Solutions (NASDAQ:VASC)
Price Target History for Vascular Solutions (NASDAQ:VASC)
Analysts' Ratings History for Vascular Solutions (NASDAQ:VASC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/5/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/5/2016Canaccord GenuityDowngradeBuy -> HoldN/AView Rating Details
12/2/2016Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
12/2/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
7/12/2016SidotiDowngradeBuy -> Neutral$47.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Vascular Solutions (NASDAQ:VASC)
Earnings by Quarter for Vascular Solutions (NASDAQ:VASC)
Earnings History by Quarter for Vascular Solutions (NASDAQ VASC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2016Q3$0.30$0.31$41.60 million$41.77 millionViewListenView Earnings Details
7/25/2016Q216$0.30$0.33$41.40 million$41.20 millionViewListenView Earnings Details
4/25/2016Q116$0.23$0.25$38.37 million$39.00 millionViewListenView Earnings Details
1/21/2016Q415$0.27$0.33$37.53 million$38.09 millionViewListenView Earnings Details
10/20/2015Q315$0.25$0.27$36.41 million$37.00 millionViewListenView Earnings Details
7/21/2015Q215$0.25$0.29$35.59 million$37.60 millionViewListenView Earnings Details
4/21/2015Q115$0.18$0.21$33.38 million$34.61 millionViewN/AView Earnings Details
2/3/2015Q414$0.18$0.23$32.82 million$33.60 millionViewN/AView Earnings Details
10/21/2014Q314$0.20$0.15$31.10 million$31.90 millionViewListenView Earnings Details
7/22/2014Q214$0.18$0.20$30.43 million$30.70 millionViewN/AView Earnings Details
4/22/2014Q114$0.18$0.16$29.91 million$29.91 millionViewListenView Earnings Details
2/4/2014Q413$0.19$0.22$28.61 million$29.10 millionViewListenView Earnings Details
10/22/2013Q313$0.07$0.19$27.10 million$28.01 millionViewListenView Earnings Details
7/23/2013Q2 2013$0.17$0.17$27.00 million$27.40 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.15$0.16$26.51 million$26.10 millionViewListenView Earnings Details
2/5/2013Q4 2012$0.17$0.18$25.59 million$25.30 millionViewListenView Earnings Details
10/18/2012$0.15$0.16ViewN/AView Earnings Details
7/24/2012$0.13$0.15ViewN/AView Earnings Details
2/1/2012$0.13$0.13ViewN/AView Earnings Details
10/25/2011$0.17$0.10ViewN/AView Earnings Details
8/2/2011$0.12$0.13ViewN/AView Earnings Details
4/19/2011$0.10$0.10ViewN/AView Earnings Details
2/1/2011$0.12$0.12ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vascular Solutions (NASDAQ:VASC)
Current Year EPS Consensus Estimate: $1.24 EPS
Next Year EPS Consensus Estimate: $1.47 EPS


Dividend History for Vascular Solutions (NASDAQ:VASC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vascular Solutions (NASDAQ:VASC)
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 80.18%
Insider Trades by Quarter for Vascular Solutions (NASDAQ:VASC)
Institutional Ownership by Quarter for Vascular Solutions (NASDAQ:VASC)
Insider Trades by Quarter for Vascular Solutions (NASDAQ:VASC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Chad KuglerVPSell1,849$55.70$102,989.30View SEC Filing  
7/27/2016Howard RootCEOSell40,000$45.11$1,804,400.00View SEC Filing  
7/27/2016William RutsteinVPSell10,011$46.26$463,108.86View SEC Filing  
5/24/2016Howard RootCEOSell34,418$39.05$1,344,022.90View SEC Filing  
5/13/2016James HennenCFOSell11,785$38.12$449,244.20View SEC Filing  
5/13/2016Martin J EmersonDirectorSell20,000$37.93$758,600.00View SEC Filing  
4/28/2016John L ErbDirectorSell10,000$35.58$355,800.00View SEC Filing  
4/27/2016Howard RootCEOSell15,582$36.07$562,042.74View SEC Filing  
4/27/2016Timothy SlaytonInsiderSell2,994$36.72$109,939.68View SEC Filing  
2/29/2016Charmaine SuttonVPSell14,325$30.13$431,612.25View SEC Filing  
11/19/2015Jorge SaucedoDirectorSell7,715$33.45$258,066.75View SEC Filing  
11/4/2015Richard NigonDirectorSell8,000$32.40$259,200.00View SEC Filing  
11/2/2015Howard RootCEOSell18,062$32.03$578,525.86View SEC Filing  
10/26/2015Carrie PowersVPSell5,412$32.77$177,351.24View SEC Filing  
8/20/2015Jorge SaucedoDirectorSell2,285$38.00$86,830.00View SEC Filing  
7/23/2015Timothy SlaytonInsiderSell1,587$38.61$61,274.07View SEC Filing  
5/28/2015Richard NigonDirectorSell6,000$32.68$196,080.00View SEC Filing  
5/4/2015Howard RootCEOSell25,000$32.62$815,500.00View SEC Filing  
4/27/2015Carrie PowersVPSell6,000$34.90$209,400.00View SEC Filing  
4/24/2015James HennenCFOSell4,792$35.66$170,882.72View SEC Filing  
2/10/2015William RutsteinVPSell10,814$26.91$291,004.74View SEC Filing  
2/5/2015James HennenCFOSell11,301$27.62$312,133.62View SEC Filing  
2/5/2015Jorge SaucedoDirectorSell10,000$27.36$273,600.00View SEC Filing  
11/26/2014Richard NigonDirectorBuy3,000$25.80$77,400.00View SEC Filing  
11/14/2014Richard W KrampDirectorBuy1,475$23.69$34,942.75View SEC Filing  
4/24/2014Timothy SlaytonInsiderSell1,390$23.15$32,178.50View SEC Filing  
2/27/2014James HennenCFOSell10,000$25.42$254,200.00View SEC Filing  
2/25/2014Howard RootCEOSell50,000$24.74$1,237,000.00View SEC Filing  
2/25/2014Richard NigonDirectorBuy1,000$25.66$25,660.00View SEC Filing  
2/14/2014Howard RootCEOSell25,000$25.13$628,250.00View SEC Filing  
2/11/2014Paul O'connellDirectorSell2,000$24.43$48,860.00View SEC Filing  
2/10/2014William RutsteinVPSell27,782$23.80$661,211.60View SEC Filing  
10/28/2013James HennenCFOSell10,000$19.72$197,200.00View SEC Filing  
10/25/2013Jorge SaucedoDirectorSell2,000$19.70$39,400.00View SEC Filing  
7/26/2013Charmaine SuttonVPSell7,538$16.15$121,738.70View SEC Filing  
7/25/2013Howard RootCEOSell21,580$16.10$347,438.00View SEC Filing  
7/25/2013Howard RootCEOSell21,580$16.10$347,438.00View SEC Filing  
7/25/2013Paul O'connellDirectorSell30,000$16.11$483,300.00View SEC Filing  
5/17/2013Paul O'connellDirectorSell10,000$16.05$160,500.00View SEC Filing  
5/1/2013Richard NigonDirectorBuy3,000$15.57$46,710.00View SEC Filing  
11/26/2012Susan ChristianVPSell7,648$14.41$110,207.68View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Vascular Solutions (NASDAQ:VASC)
Latest Headlines for Vascular Solutions (NASDAQ:VASC)
DateHeadline logoVascular Solutions (VASC) & Myriad Genetics (MYGN) Critical Survey - September 9 at 2:12 AM logoAnalyzing VAREX IMAGING (VREX) and Vascular Solutions (VASC) - September 5 at 10:22 AM logoHead-To-Head Analysis: Vascular Solutions (VASC) vs. Myriad Genetics (MYGN) - September 3 at 4:02 AM logoFinancial Comparison: Myriad Genetics (MYGN) vs. Vascular Solutions (VASC) - August 30 at 4:26 PM logoReviewing Vascular Solutions (VASC) & Myriad Genetics (MYGN) - August 29 at 8:06 PM logoComparing Vascular Solutions (VASC) and Cepheid (CPHD) - August 27 at 12:28 AM logoHead-To-Head Comparison: Vascular Solutions (VASC) and Varex Imaging (VREX) - August 25 at 4:30 PM logoFinancial Analysis: Varex Imaging (VREX) & Vascular Solutions (VASC) - August 18 at 6:14 PM logoFinancial Contrast: Cepheid (CPHD) & Vascular Solutions (NASDAQ:VASC) - August 10 at 3:02 PM logoTeleflex (TFX) Q2 2017 Results - Earnings Call Transcript - August 4 at 9:37 AM logoVascular Solutions (VASC) versus Cepheid (CPHD) Head-To-Head Contrast - August 4 at 7:42 AM logoHead to Head Survey: Vascular Solutions (VASC) & Sequenom (SQNM) - July 13 at 8:30 PM logoHead to Head Survey: Oxford Immunotec Global PLC (OXFD) & Vascular Solutions (VASC) - July 1 at 8:12 AM logoBRIEF-Teleflex's (TFX) Vascular Solutions issues recall of venture catheters - June 22 at 7:31 PM logoTeleflex’s (TFX) Vascular Solutions, Inc. Issues Recall of Venture ® Catheters - June 22 at 7:31 PM logoTeleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris - May 16 at 8:24 AM logoSunshine Heart Hires Gordon Weber as Vice President, General Counsel - May 16 at 8:24 AM logoTeleflex Lifts 2017 Profit View - May 4 at 9:49 AM logo1:01 pm Index Changes Reminder: Progenics Pharmaceuticals (PGNX) replaced Calamos Asset (CLMS) in the S&P SmallCap 600 this morning; and Shutterfly ( - February 23 at 3:06 AM logoVASCULAR SOLUTIONS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition - February 22 at 10:46 AM logoVASCULAR SOLUTIONS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi - February 17 at 5:57 AM logoVascular Solutions CEO Howard Root stands to receive $8M in sale of company - January 19 at 4:18 PM logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Shareholders To Contact The Firm For Additional ... - December 18 at 4:04 AM logoSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Investors To Contact The Firm For Additional ... - December 14 at 8:19 AM logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Vascular Solutions, Inc. to Teleflex Incorporated for $24 Per Share is Fair to ... - December 7 at 9:13 PM logoCompany News for December 05, 2016 - December 5 at 3:56 PM logoRyan & Maniskas, LLP Announces Investigation of Vascular Solutions, Inc. - December 5 at 3:56 PM logoVASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Teleflex Incorporated - December 5 at 3:56 PM logoMedical device maker Teleflex to buy Vascular Solutions for $1 billion - December 3 at 9:37 AM



Vascular Solutions (VASC) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.